{"id":"NCT01396512","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers","officialTitle":"Immunogenicity and Safety of a Single Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) in Comparison With a Single Dose of SA14-14-2 Vaccine (CD.JEVAX™, Chengdu Institute of Biological Products, China) Administered in Healthy Toddlers in South-Korea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-03","completion":"2013-06","firstPosted":"2011-07-18","resultsPosted":"2014-04-25","lastUpdate":"2014-04-25"},"enrollment":274,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis","Japanese Encephalitis Virus Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Live attenuated Japanese encephalitis chimeric virus vaccine","otherNames":["IMOJEV™"]},{"type":"BIOLOGICAL","name":"Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)","otherNames":["CD.JEVAX™"]}],"arms":[{"label":"IMOJEV™ Vaccine Group","type":"EXPERIMENTAL"},{"label":"CD.JEVAX ™ Vaccine Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) with Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine \\[CD.JEVAX™\\]) after a single dose vaccination to support product registration.\n\nPrimary Objective:\n\n* To demonstrate the non-inferiority of the antibody response 28 days after administration of one dose of IMOJEV™ compared to the antibody response 28 days after administration of one dose of the CD.JEVAX™ control vaccine.\n\nSecondary Objectives:\n\n* To describe the immune response to Japanese encephalitis (JE) in both vaccine groups using 50% plaque reduction neutralization assay (PRNT50) assays before and after a single dose of IMOJEV™ vaccine or a single dose of CD.JEVAX™ vaccine.\n* To describe the safety of vaccination in all subjects up to 28 days and all serious adverse events up to 6-month after vaccination.","primaryOutcome":{"measure":"Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine","timeFrame":"Day 28 post-vaccination","effectByArm":[{"arm":"IMOJEV™ Vaccine Group","deltaMin":100,"sd":null},{"arm":"CD.JEVAX™ Vaccine Group","deltaMin":99.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":6,"countries":["South Korea"]},"refs":{"pmids":["25483480"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":137},"commonTop":["Nasopharyngitis","Appetite Loss","Injection site Pain","Fever","Irritability"]}}